MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 04-29-2026
Country |
 USA |
IPO year |
1991 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBALSPB |
Shares |
105 M |
Market Cap[1] |
$ 66.6 B |
EBITDA (LTM) |
$ 3.4 B |
P/E (LTM) |
17.47 |
P/S (LTM) |
5.24 |
EPS (LTM) |
40.21 |
Regeneron Pharmaceuticals is an American biotechnology company that specializes in the development and production of innovative medical treatments. The company was founded in 1988 in New York.
Regeneron Pharmaceuticals' main areas of focus are research and development of drugs for the treatment of various diseases, including oncological, autoimmune, infectious, and others.
One of the company's most well-known products is Eylea, which is used to treat age-related macular degeneration. In addition, Regeneron Pharmaceuticals is developing drugs for the treatment of cancer, Alzheimer's disease, Parkinson's disease, and other conditions.
The company invests heavily in scientific research and development to create innovative and effective drugs. Regeneron Pharmaceuticals collaborates with universities, research centers, and other companies to expand its scientific potential and improve its products.
Regeneron Pharmaceuticals has a wide network of distributors and partners around the world, enabling it to provide its products to patients in various countries. The company strives for continuous improvement of its products and expansion of its activities to meet the needs of patients worldwide.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
- | 5743.5 % | $ 69.7 M | Nasdaq Capital Market |  Canada |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
- | 1.35 % | $ 17.8 M | Nasdaq Capital Market |  China |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market |  France |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market | France |
 |
AstraZeneca PLC
AZN
|
- | - | $ 96.9 B | Nasdaq Global Select Market |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Athira Pharma
ATHA
|
- | - | $ 269 M | Nasdaq Global Select Market | USA |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
- | 0.74 % | $ 768 M | Nasdaq Capital Market |  Israel |
 |
Galera Therapeutics
GRTX
|
- | -32.59 % | $ 7.61 M | Nasdaq Global Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
Esperion Therapeutics
ESPR
|
$ 3.13 | - | $ 651 M | Nasdaq Global Market,SPB | USA |
 |
Eton Pharmaceuticals
ETON
|
$ 33.24 | -5.01 % | $ 894 M | Nasdaq Global Market | USA |
|
Forte Biosciences
FBRX
|
$ 22.01 | 0.02 % | $ 285 M | Nasdaq Capital Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
- | - | $ 231 M | Nasdaq Global Market | USA |
 |
Celyad Oncology SA
CYAD
|
- | - | $ 12.5 M | Nasdaq Global Market |  Belgium |
 |
Berkeley Lights
BLI
|
- | -7.31 % | $ 87 M | Nasdaq Global Select Market | USA |
 |
Generation Bio Co.
GBIO
|
- | - | $ 344 M | Nasdaq Global Select Market | USA |
 |
IMV
IMV
|
- | - | $ 13.1 M | Nasdaq Global Select Market | Canada |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
BioNTech SE
BNTX
|
$ 93.43 | 2.75 % | $ 22.6 B | Nasdaq Global Select Market | Germany |
 |
Grifols, S.A.
GRFS
|
$ 7.98 | -1.66 % | $ 5.42 B | Nasdaq Global Select Market |  Spain |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.75 | 6.06 % | $ 466 M | Nasdaq Global Select Market | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | Israel |
 |
Heron Therapeutics
HRTX
|
$ 0.88 | 1.24 % | $ 147 M | Nasdaq Global Select Market,SPB | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
- | -4.36 % | $ 27 M | Nasdaq Capital Market | USA |
 |
Compugen Ltd.
CGEN
|
$ 2.84 | 8.81 % | $ 265 M | Nasdaq Global Market,SPB | Israel |
 |
Anika Therapeutics
ANIK
|
$ 14.85 | -1.17 % | $ 213 M | Nasdaq Global Select Market,SPB | USA |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
Incyte Corporation
INCY
|
$ 97.05 | -0.37 % | $ 18.9 B | Nasdaq Global Select Market,SPB | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market | Canada |
 |
Ionis Pharmaceuticals
IONS
|
$ 75.54 | -0.32 % | $ 12.1 B | Nasdaq Global Select Market,SPB | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 3.43 | -0.29 % | $ 5.65 M | NYSE American | Israel |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
Coherus BioSciences
CHRS
|
$ 1.64 | 4.14 % | $ 192 M | Nasdaq Global Market | USA |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 20.78 | -1.09 % | $ 2.64 B | Nasdaq Global Select Market,SPB | USA |
 |
Allena Pharmaceuticals
ALNA
|
- | 3.16 % | $ 1.9 M | Nasdaq Global Select Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.